Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Approves Ivosidenib for Frontline IDH1+ AML

May 2nd 2019

The FDA has approved a supplemental new drug application for ivosidenib as a single agent for the first-line treatment of adult patients with IDH1-mutant acute myeloid leukemia, as detected by an FDA-approved test, who are ≥75 years old or are ineligible to receive intensive chemotherapy.

New Era Begins of Molecular Monitoring and Targeted Therapy in AML

May 2nd 2019

Eric S. Winer, MD, highlights the targeted therapies that have made the biggest clinical impact for patients with acute myeloid leukemia.

Venetoclax Spearheads Myriad of AML Advances

May 1st 2019

Jacqueline S. Garcia, MD, highlights key progress made in acute myeloid leukemia and remaining questions with maintenance strategies.

TKI Discontinuation Safe in CML, But Patient Selection Is Key

May 1st 2019

Although TKIs have significantly improved life expectancy for patients with chronic myeloid leukemia, investigators are actively examining ways to safely discontinue treatment without sacrificing benefit.

Dr. Bianchi on Shifting Landscape of Transplant Eligible Myeloma

April 30th 2019

Giada Bianchi, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, discusses treatment options for transplant eligible patients with multiple myeloma.

Treatment Options Expanding for Benign Hematologic Disorders

April 30th 2019

Nathan T. Connell, MD, MPH, shares key updates in the rapidly evolving treatment paradigms of benign hematologic disorders.

Dr. Nadeem on Sequencing Considerations in Multiple Myeloma

April 29th 2019

Omar Nadeem, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, discusses sequencing challenges in multiple myeloma.

Research Propels Forward With CAR T-Cell Therapy in Pediatric ALL

April 28th 2019

Christine N. Duncan, MD, discusses the current components of CAR T-cell therapy in pediatric acute lymphoblastic leukemia.

European Approval Sought for Luspatercept for Anemias

April 26th 2019

A marketing authorization application has been submitted to the European Medicines Agency for luspatercept for the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndrome–associated anemia with ring sideroblasts who require red blood cell transfusions and have not received or are ineligible to receive erythropoiesis-stimulating agents.

Frontline Lenalidomide/R-CHOP Combo Misses Primary Endpoint in DLBCL

April 26th 2019

The combination of lenalidomide (Revlimid) with rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; R2-CHOP) did not improve progression-free survival compared with placebo and R-CHOP as a frontline therapy in patients with activated B-cell-type diffuse large B-cell lymphoma, missing the primary endpoint of the phase III ROBUST trial.

Dr. Mullighan on Germline Predisposition to ALL

April 26th 2019

Charles G. Mullighan, MBBS, MSc, MD, member, St. Jude Faculty, deputy director, Comprehensive Cancer Center, co-leader, Hematological Malignancies Program, medical director, St. Jude Biorepository, William E. Evans Endowed Chair, St. Jude Children’s Research Hospital, discusses germline predisposition to acute lymphoblastic leukemia (ALL).

Tagraxofusp Elicits Responses in Treatment-Naive and Relapsed BPDCN

April 25th 2019

Tagraxofusp led to a 90% overall response rate as a first-line therapy in patients with blastic plasmacytoid dendritic cell neoplasm.

Dr. Shah on TKI Treatment Discontinuation in CML

April 24th 2019

Neil P. Shah, MD, PhD, professor of medicine, Division of Hematology and Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses TKI treatment discontinuation in patients with chronic myeloid leukemia.

Metastatic Cancer Is a Chronic Condition

April 23rd 2019

Advancements in targeted therapy and immunotherapy have led to a rapidly increasing number of patients with metastatic cancer becoming patients with chronic cancer.

Sequencing Challenges Emerge in Myeloma as Options Expand

April 22nd 2019

Omar Nadeem, MD, highlights exciting approaches that have emerged in relapsed/refractory myeloma, such as CAR T-cell therapy, and shares unanswered questions that future research should address.

Monoclonal Antibodies Shake Up Myeloma Paradigm

April 22nd 2019

Paul G. Richardson, MD, highlights the many promising agents that have emerged in relapsed/refractory multiple myeloma in recent years, remaining challenges, and hope for continued progress.

FDA Schedules ODAC Meetings for Pexidartinib in TGCT and Quizartinib in AML

April 19th 2019

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for May 14, 2019, to discuss a new drug application for pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor.

Daratumumab Elicits Low Responses in Relapsed/Refractory Non-Hodgkin Lymphoma

April 17th 2019

Daratumumab was associated with low overall response rates in patients with relapsed/refractory diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma, missing the primary endpoint of a phase II trial published in Clinical Lymphoma, Myeloma & Leukemia.1

Ivosidenib Holds Greatest Benefit for Older Patients With IDH1-Mutant AML

April 16th 2019

Courtney D. DiNardo, MD, MSCE, discusses the findings of the phase I dose-escalating study that led to the initial approval of ivosidenib for adult patients with relapsed or refractory acute myeloid leukemia with an IDH1 mutation.

Quizartinib Poised to Expand FLT3 Inhibition Options in AML

April 16th 2019

Quizartinib, a novel small molecule FLT3 inhibitor, is moving through the pipeline of new drugs under development for patients with FLT3-mutated acute myeloid leukemia, part of a menu of targeted treatment options that is expanding as investigators learn more about the molecular heterogeneity of the disease.